N. Colombo
New England Journal of Medicine · 2003–2022
A researcher in the Science corpus: 12 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Whom N. Colombo trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from N. Colombo's perspective
Ordered by how strongly the researchers N. Colombo trusts endorse each paper. Same corpus, a different order for every researcher.
- Integrated Genomic Characterization of Endometrial Carcinoma (Nature)
- Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. (Radiotherapy and Oncology)
- Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. (The Lancet)
- Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (Annals of Oncology)
- Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. (Clinical Infectious Diseases)
- A clinically applicable molecular-based classification for endometrial cancers (British Journal of Cancer)
- Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial
- Post operative radiation therapy in endometrial carcinoma : reducing overtreatment and improving quality of life
- Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. (Journal of Clinical Oncology)
- Comparative Study
Their papers
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer (2022) — 681 citations
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. (2021) — 814 citations
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma (2020) — 1,756 citations
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. (2019) — 1,632 citations
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (2018) — 2,381 citations
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) — 716 citations
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) — 1,515 citations
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) — 1,446 citations
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2015) — 904 citations
- ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. (2015) — 642 citations
- Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. (2009) — 696 citations
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. (2003) — 1,166 citations